Regulation FD Disclosure

Business Context and Reporting Period

Galecto, Inc. filed a Form 8-K dated March 15, 2021 under Regulation FD. The filing concerns an independent Data Safety Monitoring Board interim review of the company’s Phase 2b GALACTIC-1 study of GB0139 for idiopathic pulmonary fibrosis.

The provided filing identifies the registrant as Galecto, Inc., although the request metadata names Damora Therapeutics, Inc.

Financial and Operating Metrics

The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.

Material Changes Versus the Prior Comparable Period

The filing reports an interim review by the independent Data Safety Monitoring Board but does not include the review’s outcome in the provided text. The associated press release is referenced as Exhibit 99.1 but was not included.

Guidance, Outlook, Risks, and Unusual Items

  • The filing relates to a clinical-trial safety review of GB0139 in idiopathic pulmonary fibrosis.
  • No specific clinical conclusions, guidance, timeline, financial outlook, or risk disclosures are provided in the filing text.
  • The information is furnished under Regulation FD and is not deemed filed under Section 18 of the Exchange Act or incorporated by reference, except where expressly stated.

Investor Verification Items

  • Obtain and review Exhibit 99.1 to determine the Data Safety Monitoring Board’s actual interim-review outcome.
  • Verify the registrant’s identity because the filing names Galecto, Inc., while the request metadata names Damora Therapeutics, Inc.
  • Assess any resulting changes to the GALACTIC-1 study, GB0139 development plans, clinical timelines, or funding needs.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.